1 of 1
Story summary
- Employees at Theramex warned that outdated prescribing information endangered hormone-replacement therapy patients.
- The Prescription Medicines Code of Practice Authority reprimanded Theramex for 21 breaches of the ABPI code.
- Theramex left the PMCPA’s self-regulatory framework in January 2026, moving regulation to the MHRA.
- MHRA executive director Julian Beach said the agency will use its legal powers to investigate any medicine safety concerns.
